Drug intelligence / Profile preview

chlorobutanol + hexetidine

Development stage: Unknown
Lead developer: Pierre Fabre
Modality: Small Molecules
Administration: Topical, Oral

Overview

Chlorobutanol + hexetidine is a combination drug used primarily for treating sore throat and oral mucositis. Hexetidine provides pronounced antibacterial activity against both gram-positive and gram-negative microorganisms, effective against aerobic and anaerobic bacteria. It has a moderate bacteriostatic effect on aerobic strains and a strong bactericidal effect on anaerobic strains. Its mechanism is based on competition with thiamine, which is necessary for microorganism growth. Chlorobutanol contributes analgesic (local anesthetic) properties to the combination, helping to reduce pain and discomfort associated with sore throat.

Brand names: Angilor

Beyond the preview

Go deeper on chlorobutanol + hexetidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chlorobutanol + hexetidine.

Explore the full profile